Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Instituto de investigación
Juan Antonio
Pineda Vergara
Publicaciones en las que colabora con Juan Antonio Pineda Vergara (25)
2022
-
Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe
Journal of Hepatology, Vol. 77, Núm. 2, pp. 326-331
2020
-
Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362
2019
-
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy
Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2014
-
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV
The Lancet Infectious Diseases
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients
Hepatology, Vol. 56, Núm. 4, pp. 1261-1270
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
2009
-
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
Hepatology, Vol. 50, Núm. 4, pp. 1056-1063
-
Natural history of compensated hepatitis c virusrelated cirrhosis in HIV-infected patients
Clinical Infectious Diseases, Vol. 49, Núm. 8, pp. 1274-1282
2008
-
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
AIDS, Vol. 22, Núm. 8, pp. 923-930
-
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796
-
Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
2007
-
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354
-
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235
-
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 4, pp. 523-529
2006
-
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C
Antiviral Therapy, Vol. 11, Núm. 7, pp. 839-846